Question to the HM Treasury:

To ask Mr Chancellor of the Exchequer, when his Department received the business case for the meningococcal B vaccine; and when he expects to make a decision whether or not to approve the business case.

On 21 March 2014, the Joint Committee on Vaccination and Immunisation (JCVI) recommended that there should be a national Meningococcal B immunisation programme for infants, if the vaccine, Bexsero ®, could be purchased at a cost-effective price. The Treasury is working closely with the Department of Health on this business case. The Government would like to secure the vaccine from the supplier at the cost-effective price recommended by the JCVI.